Literature DB >> 3805319

Morphometric data to FIGO stage and histological type and grade for prognosis of ovarian tumours.

J P Baak, E C Wisse-Brekelmans, F A Langley, A Talerman, J F Delemarre.   

Abstract

The prognostic value of using histological typing, grading, and morphology, in addition to clinical staging, was assessed in 98 cases of invasive ovarian cancer of the common epithelial types (serous, mucinous, and endometrial). All of these cases had at least five years of follow up. When regression analysis was used, the International Federation of Gynaecology and Obstetrics' (FIGO) staging system was the best indicator for prognosis. Analysis of a combination of morphometric features was the second best indicator, being especially useful for the those patients with stage I disease. Variables that indicated a relatively poor prognostic outcome were mitotic index above 30; volume percentage epithelium above 65%; shortest nuclear axis above a mean of 1 X 1 micrometers. Histological typing of ovarian tumours was of limited value; mucinous tumours have a somewhat better prognosis than serous tumours, but the prognostic value of typing alone was found to be limited. Qualitative histological grading was useful, but the prognostic value of morphometric grading was better. Measurement of morphological features with an interactive computer program is simple and can be done by a pathologist or a technician: in future it is likely that such automated systems of measurement will improve the objectivity of tissue analysis.

Entities:  

Mesh:

Year:  1986        PMID: 3805319      PMCID: PMC1140799          DOI: 10.1136/jcp.39.12.1340

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  9 in total

1.  Image processing for mitoses in sections of breast cancer: a feasibility study.

Authors:  E J Kaman; A W Smeulders; P W Verbeek; I T Young; J P Baak
Journal:  Cytometry       Date:  1984-05

2.  Quantitation of borderline and malignant mucinous ovarian tumours.

Authors:  J P Baak; A A Blanco; P H Kurver; F A Langley; M E Boon; J Lindeman; S H Overdiep; A Nieuwlaat; E Brekelmans
Journal:  Histopathology       Date:  1981-07       Impact factor: 5.087

3.  Application of DNA flow cytometry to paraffin-embedded archival material for the study of aneuploidy and its clinical significance.

Authors:  D W Hedley; M L Friedlander; I W Taylor
Journal:  Cytometry       Date:  1985-07

4.  Influence of cellular DNA content on survival in advanced ovarian cancer.

Authors:  M L Friedlander; D W Hedley; I W Taylor; P Russell; A S Coates; M H Tattersall
Journal:  Cancer Res       Date:  1984-01       Impact factor: 12.701

5.  The value of morphometry to classic prognosticators in breast cancer.

Authors:  J P Baak; H Van Dop; P H Kurver; J Hermans
Journal:  Cancer       Date:  1985-07-15       Impact factor: 6.860

6.  The prognostic value of morphometry in ovarian epithelial tumors of borderline malignancy.

Authors:  J P Baak; H Fox; F A Langley; C H Buckley
Journal:  Int J Gynecol Pathol       Date:  1985       Impact factor: 2.762

Review 7.  Peripheral aromatization as a risk factor for breast and endometrial cancer in postmenopausal women: a review.

Authors:  C L Enriori; J Reforzo-Membrives
Journal:  Gynecol Oncol       Date:  1984-01       Impact factor: 5.482

8.  Clinico-pathological correlates in ovarian cancer.

Authors:  A J Dembo; R S Bush; T C Brown
Journal:  Bull Cancer       Date:  1982       Impact factor: 1.276

9.  Borderline or malignant ovarian tumour? A case report of decision making with morphometry.

Authors:  J P Baak; G Van der Ley
Journal:  J Clin Pathol       Date:  1984-10       Impact factor: 3.411

  9 in total
  11 in total

Review 1.  Proliferation markers in tumours: interpretation and clinical value.

Authors:  P J van Diest; G Brugal; J P Baak
Journal:  J Clin Pathol       Date:  1998-10       Impact factor: 3.411

2.  Decreased expression of pyruvate dehydrogenase A1 predicts an unfavorable prognosis in ovarian carcinoma.

Authors:  Yaqing Li; Ruixia Huang; Xiaoli Li; Xiaoran Li; Dandan Yu; Mingzhi Zhang; Jianguo Wen; Mariusz Adam Goscinski; Claes G Trope; Jahn M Nesland; Zhenhe Suo
Journal:  Am J Cancer Res       Date:  2016-09-01       Impact factor: 6.166

3.  Prognostic and clinicopathological significance of Cacna2d1 expression in epithelial ovarian cancers: a retrospective study.

Authors:  Dandan Yu; Ruth Holm; Mariusz Adam Goscinski; Claes G Trope; Jahn M Nesland; Zhenhe Suo
Journal:  Am J Cancer Res       Date:  2016-09-01       Impact factor: 6.166

4.  Effects of differentiation-inducing agents on purine nucleotide metabolism in an ovarian cancer cell line.

Authors:  E Zoref-Shani; R Lavie; Y Bromberg; E Beery; Y Sidi; O Sperling; J Nordenberg
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

5.  Morphometric, DNA and PCNA in thin malignant melanomas.

Authors:  V Björnhagen; E Månsson-Brahme; J Lindholm; A Mattsson; G Auer
Journal:  Med Oncol Tumor Pharmacother       Date:  1993

6.  The prognostic value of morphometry in advanced epithelial ovarian cancers.

Authors:  M Katsoulis; J Lekka; I Vlachonikolis; G S Delides
Journal:  Br J Cancer       Date:  1995-10       Impact factor: 7.640

7.  Prognostic value of histological type in stage IV ovarian carcinoma: a retrospective analysis of 223 patients.

Authors:  M Mizuno; H Kajiyama; K Shibata; K Mizuno; M Kawai; T Nagasaka; F Kikkawa
Journal:  Br J Cancer       Date:  2015-03-24       Impact factor: 7.640

8.  The expression of aldehyde dehydrogenase 1 (ALDH1) in ovarian carcinomas and its clinicopathological associations: a retrospective study.

Authors:  Ruixia Huang; Xiaoran Li; Ruth Holm; Claes G Trope; Jahn M Nesland; Zhenhe Suo
Journal:  BMC Cancer       Date:  2015-07-07       Impact factor: 4.430

9.  Mammaglobin B is an independent prognostic marker in epithelial ovarian cancer and its expression is associated with reduced risk of disease recurrence.

Authors:  Renata A Tassi; Stefano Calza; Antonella Ravaggi; Eliana Bignotti; Franco E Odicino; Germana Tognon; Carla Donzelli; Marcella Falchetti; Elisa Rossi; Paola Todeschini; Chiara Romani; Elisabetta Bandiera; Laura Zanotti; Sergio Pecorelli; Alessandro D Santin
Journal:  BMC Cancer       Date:  2009-07-27       Impact factor: 4.430

10.  The prognostic value of morphometrical features and cellular DNA content in cis-platin treated late ovarian cancer patients.

Authors:  J P Baak; N W Schipper; E C Wisse-Brekelmans; T Ceelen; F T Bosman; H van Geuns; J Wils
Journal:  Br J Cancer       Date:  1988-05       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.